

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G2444EC9B15EEN.html>

Date: June 2026

Pages: 108

Price: US\$ 3,480.00 (Single User License)

ID: G2444EC9B15EEN

Abstracts

According to our (Global Info Research) latest study, the global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size was valued at US\$ 569 million in 2025 and is forecast to a readjusted size of US\$ 1018530 million by 2032 with a CAGR of 193.8% during review period.

Mesenchymal stem cell (MSCs) therapeutic product CDMO (Contract Development and Manufacturing Organization) services refer to a series of services from research and development to production for mesenchymal stem cell-related therapeutic products. CDMOs usually provide outsourcing services to pharmaceutical and biotechnology companies to help them develop and produce biologics in the preclinical and clinical stages.

This report is a detailed and comprehensive analysis for global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market shares of main players, in revenue (\$ Million), 2021-2026

The Primary Objectives in This Report Are:

- To determine the size of the total market opportunity of global and key countries

- To assess the growth potential for Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service

- To forecast future growth in each product and end-use market

- To assess competitive factors affecting the marketplace

This report profiles key players in the global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lonza, uBriGene Biosciences International, Thermo Fisher, Creative Biolabs, REPROCELL, ATCC, Beijing CytoNiche Biotech, OmniaBio, Histocell, FUJIFILM Diosynth Biotechnologies, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by

Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Cell Therapy

Cell-derived Products

Market segment by Application

Large Pharmaceutical Company

Small and Medium-sized Pharmaceutical Company

Market segment by players, this report covers

Lonza

uBriGene Biosciences International

Thermo Fisher

Creative Biolabs

REPROCELL

ATCC

Beijing CytoNiche Biotech

OmniaBio

Histocell

FUJIFILM Diosynth Biotechnologies

Taiwan Bio Therapeutics

Encell Co., Ltd.

Mycenax

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service, with revenue, gross margin, and global market share of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service from 2021 to 2026.

Chapter 3, the Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service

market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service.

Chapter 13, to describe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service by Type

1.3.1 Overview: Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type in 2025

1.3.3 Cell Therapy

1.3.4 Cell-derived Products

1.4 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market by Application

1.4.1 Overview: Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application: 2021 Versus 2025 Versus 2032

1.4.2 Large Pharmaceutical Company

1.4.3 Small and Medium-sized Pharmaceutical Company

1.5 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size & Forecast

1.6 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast by Region

1.6.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region: 2021 VS 2025 VS 2032

1.6.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region, (2021-2032)

1.6.3 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Prospect (2021-2032)

1.6.4 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Prospect (2021-2032)

1.6.5 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Prospect (2021-2032)

1.6.6 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Prospect (2021-2032)

1.6.7 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 Lonza

2.1.1 Lonza Details

2.1.2 Lonza Major Business

2.1.3 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.1.4 Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.1.5 Lonza Recent Developments and Future Plans

2.2 uBriGene Biosciences International

2.2.1 uBriGene Biosciences International Details

2.2.2 uBriGene Biosciences International Major Business

2.2.3 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.2.4 uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.2.5 uBriGene Biosciences International Recent Developments and Future Plans

2.3 Thermo Fisher

2.3.1 Thermo Fisher Details

2.3.2 Thermo Fisher Major Business

2.3.3 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.3.4 Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.3.5 Thermo Fisher Recent Developments and Future Plans

2.4 Creative Biolabs

2.4.1 Creative Biolabs Details

2.4.2 Creative Biolabs Major Business

2.4.3 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.4.4 Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.4.5 Creative Biolabs Recent Developments and Future Plans

2.5 REPROCELL

2.5.1 REPROCELL Details

2.5.2 REPROCELL Major Business

2.5.3 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.5.4 REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.5.5 REPROCELL Recent Developments and Future Plans

2.6 ATCC

2.6.1 ATCC Details

2.6.2 ATCC Major Business

2.6.3 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.6.4 ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.6.5 ATCC Recent Developments and Future Plans

2.7 Beijing CytoNiche Biotech

2.7.1 Beijing CytoNiche Biotech Details

2.7.2 Beijing CytoNiche Biotech Major Business

2.7.3 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.7.4 Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.7.5 Beijing CytoNiche Biotech Recent Developments and Future Plans

2.8 OmniaBio

2.8.1 OmniaBio Details

2.8.2 OmniaBio Major Business

2.8.3 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.8.4 OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.8.5 OmniaBio Recent Developments and Future Plans

2.9 Histocell

2.9.1 Histocell Details

2.9.2 Histocell Major Business

2.9.3 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

2.9.4 Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 Histocell Recent Developments and Future Plans

2.10 FUJIFILM Diosynth Biotechnologies

2.10.1 FUJIFILM Diosynth Biotechnologies Details

2.10.2 FUJIFILM Diosynth Biotechnologies Major Business

2.10.3 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs)

Therapeutic Product CDMO Service Product and Solutions

2.10.4 FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs)

Therapeutic Product CDMO Service Revenue, Gross Margin and Market Share
(2021-2026)

2.10.5 FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans

2.11 Taiwan Bio Therapeutics

2.11.1 Taiwan Bio Therapeutics Details

2.11.2 Taiwan Bio Therapeutics Major Business

2.11.3 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product
CDMO Service Product and Solutions

2.11.4 Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product
CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 Taiwan Bio Therapeutics Recent Developments and Future Plans

2.12 Encell Co., Ltd.

2.12.1 Encell Co., Ltd. Details

2.12.2 Encell Co., Ltd. Major Business

2.12.3 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO
Service Product and Solutions

2.12.4 Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO
Service Revenue, Gross Margin and Market Share (2021-2026)

2.12.5 Encell Co., Ltd. Recent Developments and Future Plans

2.13 Mycenax

2.13.1 Mycenax Details

2.13.2 Mycenax Major Business

2.13.3 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service
Product and Solutions

2.13.4 Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service
Revenue, Gross Margin and Market Share (2021-2026)

2.13.5 Mycenax Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service
Revenue and Share by Players (2021-2026)

3.2 Market Share Analysis (2025)

3.2.1 Market Share of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO
Service by Company Revenue

3.2.2 Top 3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service
Players Market Share in 2025

3.2.3 Top 6 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players Market Share in 2025

3.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market: Overall Company Footprint Analysis

3.3.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market: Region Footprint

3.3.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market: Company Product Type Footprint

3.3.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market: Company Product Application Footprint

3.4 New Market Entrants and Barriers to Market Entry

3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

4.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value and Market Share by Type (2021-2026)

4.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

5.1 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application (2021-2026)

5.2 Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Forecast by Application (2027-2032)

6 NORTH AMERICA

6.1 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2032)

6.2 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Application (2021-2032)

6.3 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country

6.3.1 North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2032)

6.3.2 United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

6.3.3 Canada Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

6.3.4 Mexico Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

7 EUROPE

7.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2032)

7.2 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2032)

7.3 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country

7.3.1 Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2032)

7.3.2 Germany Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

7.3.3 France Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

7.3.4 United Kingdom Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

7.3.5 Russia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

7.3.6 Italy Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

8.1 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2032)

8.2 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2032)

8.3 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Region

8.3.1 Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Region (2021-2032)

8.3.2 China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

8.3.3 Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service

Market Size and Forecast (2021-2032)

8.3.4 South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

8.3.5 India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

8.3.6 Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

8.3.7 Australia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

9.1 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2032)

9.2 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2032)

9.3 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country

9.3.1 South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2032)

9.3.2 Brazil Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

9.3.3 Argentina Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2032)

10.2 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2032)

10.3 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size by Country

10.3.1 Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2032)

10.3.2 Turkey Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

10.3.4 UAE Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers

11.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints

11.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industry Chain

12.2 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Upstream Analysis

12.3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Midstream Analysis

12.4 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 3. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Region (2021-2026) & (USD Million)

Table 4. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Region (2027-2032) & (USD Million)

Table 5. Lonza Company Information, Head Office, and Major Competitors

Table 6. Lonza Major Business

Table 7. Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 8. Lonza Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 9. Lonza Recent Developments and Future Plans

Table 10. uBriGene Biosciences International Company Information, Head Office, and Major Competitors

Table 11. uBriGene Biosciences International Major Business

Table 12. uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 13. uBriGene Biosciences International Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 14. uBriGene Biosciences International Recent Developments and Future Plans

Table 15. Thermo Fisher Company Information, Head Office, and Major Competitors

Table 16. Thermo Fisher Major Business

Table 17. Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 18. Thermo Fisher Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 19. Creative Biolabs Company Information, Head Office, and Major Competitors

Table 20. Creative Biolabs Major Business

Table 21. Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 22. Creative Biolabs Mesenchymal Stem Cell (MSCs) Therapeutic Product

CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 23. Creative Biolabs Recent Developments and Future Plans

Table 24. REPROCELL Company Information, Head Office, and Major Competitors

Table 25. REPROCELL Major Business

Table 26. REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 27. REPROCELL Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 28. REPROCELL Recent Developments and Future Plans

Table 29. ATCC Company Information, Head Office, and Major Competitors

Table 30. ATCC Major Business

Table 31. ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 32. ATCC Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 33. ATCC Recent Developments and Future Plans

Table 34. Beijing CytoNiche Biotech Company Information, Head Office, and Major Competitors

Table 35. Beijing CytoNiche Biotech Major Business

Table 36. Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 37. Beijing CytoNiche Biotech Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 38. Beijing CytoNiche Biotech Recent Developments and Future Plans

Table 39. OmniaBio Company Information, Head Office, and Major Competitors

Table 40. OmniaBio Major Business

Table 41. OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 42. OmniaBio Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 43. OmniaBio Recent Developments and Future Plans

Table 44. Histocell Company Information, Head Office, and Major Competitors

Table 45. Histocell Major Business

Table 46. Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 47. Histocell Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 48. Histocell Recent Developments and Future Plans

Table 49. FUJIFILM Diosynth Biotechnologies Company Information, Head Office, and Major Competitors

Table 50. FUJIFILM Diosynth Biotechnologies Major Business

Table 51. FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 52. FUJIFILM Diosynth Biotechnologies Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 53. FUJIFILM Diosynth Biotechnologies Recent Developments and Future Plans

Table 54. Taiwan Bio Therapeutics Company Information, Head Office, and Major Competitors

Table 55. Taiwan Bio Therapeutics Major Business

Table 56. Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 57. Taiwan Bio Therapeutics Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 58. Taiwan Bio Therapeutics Recent Developments and Future Plans

Table 59. Encell Co., Ltd. Company Information, Head Office, and Major Competitors

Table 60. Encell Co., Ltd. Major Business

Table 61. Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 62. Encell Co., Ltd. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 63. Encell Co., Ltd. Recent Developments and Future Plans

Table 64. Mycenax Company Information, Head Office, and Major Competitors

Table 65. Mycenax Major Business

Table 66. Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Product and Solutions

Table 67. Mycenax Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 68. Mycenax Recent Developments and Future Plans

Table 69. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue (USD Million) by Players (2021-2026)

Table 70. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Share by Players (2021-2026)

Table 71. Breakdown of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3)

Table 72. Market Position of Players in Mesenchymal Stem Cell (MSCs) Therapeutic

Product CDMO Service, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 73. Head Office of Key Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players

Table 74. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market: Company Product Type Footprint

Table 75. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market: Company Product Application Footprint

Table 76. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service New Market Entrants and Barriers to Market Entry

Table 77. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Mergers, Acquisition, Agreements, and Collaborations

Table 78. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (USD Million) by Type (2021-2026)

Table 79. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Share by Type (2021-2026)

Table 80. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Forecast by Type (2027-2032)

Table 81. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2026)

Table 82. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Forecast by Application (2027-2032)

Table 83. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2026) & (USD Million)

Table 84. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2027-2032) & (USD Million)

Table 85. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2026) & (USD Million)

Table 86. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2027-2032) & (USD Million)

Table 87. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2026) & (USD Million)

Table 88. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2027-2032) & (USD Million)

Table 89. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2026) & (USD Million)

Table 90. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2027-2032) & (USD Million)

Table 91. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2026) & (USD Million)

Table 92. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2027-2032) & (USD Million)

Table 93. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2026) & (USD Million)

Table 94. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2027-2032) & (USD Million)

Table 95. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2026) & (USD Million)

Table 96. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2027-2032) & (USD Million)

Table 97. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2026) & (USD Million)

Table 98. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2027-2032) & (USD Million)

Table 99. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Region (2021-2026) & (USD Million)

Table 100. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Region (2027-2032) & (USD Million)

Table 101. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2026) & (USD Million)

Table 102. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2027-2032) & (USD Million)

Table 103. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2026) & (USD Million)

Table 104. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2027-2032) & (USD Million)

Table 105. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2021-2026) & (USD Million)

Table 106. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Country (2027-2032) & (USD Million)

Table 107. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2021-2026) & (USD Million)

Table 108. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type (2027-2032) & (USD Million)

Table 109. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2021-2026) & (USD Million)

Table 110. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application (2027-2032) & (USD Million)

Table 111. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product

CDMO Service Consumption Value by Country (2021-2026) & (USD Million)

Table 112. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product

CDMO Service Consumption Value by Country (2027-2032) & (USD Million)

Table 113. Global Key Players of Mesenchymal Stem Cell (MSCs) Therapeutic Product

CDMO Service Upstream (Raw Materials)

Table 114. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service

Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Picture
- Figure 2. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type in 2025
- Figure 4. Cell Therapy
- Figure 5. Cell-derived Products
- Figure 6. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
- Figure 7. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application in 2025
- Figure 8. Large Pharmaceutical Company Picture
- Figure 9. Small and Medium-sized Pharmaceutical Company Picture
- Figure 10. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value, (USD Million): 2021 & 2025 & 2032
- Figure 11. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value and Forecast (2021-2032) & (USD Million)
- Figure 12. Global Market Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
- Figure 13. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Region (2021-2032)
- Figure 14. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Region in 2025
- Figure 15. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 16. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 17. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 18. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 19. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)
- Figure 20. Company Three Recent Developments and Future Plans

Figure 21. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Revenue Share by Players in 2025

Figure 22. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 23. Market Share of Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service by Player Revenue in 2025

Figure 24. Top 3 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players Market Share in 2025

Figure 25. Top 6 Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Players Market Share in 2025

Figure 26. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Share by Type (2021-2026)

Figure 27. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share Forecast by Type (2027-2032)

Figure 28. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Share by Application (2021-2026)

Figure 29. Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Share Forecast by Application (2027-2032)

Figure 30. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type (2021-2032)

Figure 31. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application (2021-2032)

Figure 32. North America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Country (2021-2032)

Figure 33. United States Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 34. Canada Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 35. Mexico Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 36. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type (2021-2032)

Figure 37. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application (2021-2032)

Figure 38. Europe Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Country (2021-2032)

Figure 39. Germany Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 40. France Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service

Consumption Value (2021-2032) & (USD Million)

Figure 41. United Kingdom Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 42. Russia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 43. Italy Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 44. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type (2021-2032)

Figure 45. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application (2021-2032)

Figure 46. Asia-Pacific Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Region (2021-2032)

Figure 47. China Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 48. Japan Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 49. South Korea Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 50. India Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 51. Southeast Asia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 52. Australia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 53. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type (2021-2032)

Figure 54. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application (2021-2032)

Figure 55. South America Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Country (2021-2032)

Figure 56. Brazil Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 57. Argentina Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 58. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Type (2021-2032)

Figure 59. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Application (2021-2032)

Figure 60. Middle East & Africa Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value Market Share by Country (2021-2032)

Figure 61. Turkey Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 62. Saudi Arabia Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 63. UAE Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Consumption Value (2021-2032) & (USD Million)

Figure 64. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Drivers

Figure 65. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Restraints

Figure 66. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market Trends

Figure 67. Porters Five Forces Analysis

Figure 68. Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Industrial Chain

Figure 69. Methodology

Figure 70. Research Process and Data Source

I would like to order

Product name: Global Mesenchymal Stem Cell (MSCs) Therapeutic Product CDMO Service Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G2444EC9B15EEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G2444EC9B15EEN.html>